Chemotherapy News and Research

Latest Chemotherapy News and Research

Survey shows ongoing misconceptions about hormone therapy safety in cancer survivors

Despite evidence suggesting the safety of hormone therapy for patients with a history of low-grade endometrial or epithelial ovarian cancer, a new survey shows that many gynecologists and some gynecologic oncologists are still uncomfortable prescribing the therapy for this patient population.

10 Sep 2025

Research warns of lasting health impacts from muscle loss in young cancer patients

New research from the Exercise Medicine Research Institute at Edith Cowan University (ECU) has highlighted that children undergoing cancer treatment often lose skeletal muscle at a time when they should be rapidly gaining it, a loss that could increase treatment complications and raise the risk of long-term health problems.

10 Sep 2025

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.

10 Sep 2025

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

9 Sep 2025

Exploring whether chemotherapy disrupts biological clock in the brain to impair circadian rhythms

During and after chemotherapy, nearly half of cancer patients endure circadian rhythm disruptions, which worsens treatment side effects.

9 Sep 2025

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Creatine increases muscle strength in Alzheimer’s patients

Research indicates that creatine may enhance muscle strength and size in Alzheimer's patients, suggesting a viable approach for mitigating muscle loss.

8 Sep 2025

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents.

3 Sep 2025

New drug dismantles cancer cell powerhouse to halt tumor growth

Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers.

2 Sep 2025

Breakthrough discovery reveals treatable form of familial mesothelioma

Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of mesothelioma that may lead to more successful treatments.

2 Sep 2025

ESC and EAS release new dyslipidaemia guidelines

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) have just published the new international recommendations for managing dyslipidaemias. They were presented at the Annual Cardiology Congress held in Madrid from August 29th to September 1st, 2025.

2 Sep 2025

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC/EAS Focused Update to Guidelines, about how best to manage lipid levels in patients to reduce cardiovascular risk, recommends the use of new cardiovascular risk predication algorithms. The update was published today at ESC Congress 2025.

30 Aug 2025

Disrupting protein quality control slows tumor growth in pediatric rhabdomyosarcoma

A new research paper was published in Volume 16 of Oncotarget on August 29, 2025, titled "In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma."

29 Aug 2025

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.

28 Aug 2025

Chemotherapy News and Research

Latest Chemotherapy News and Research

Survey shows ongoing misconceptions about hormone therapy safety in cancer survivors

Research warns of lasting health impacts from muscle loss in young cancer patients

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

Exploring whether chemotherapy disrupts biological clock in the brain to impair circadian rhythms

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Creatine increases muscle strength in Alzheimer’s patients

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

New drug dismantles cancer cell powerhouse to halt tumor growth

Breakthrough discovery reveals treatable form of familial mesothelioma

ESC and EAS release new dyslipidaemia guidelines

ESC releases new guidance on lipid management to reduce cardiovascular risk

Disrupting protein quality control slows tumor growth in pediatric rhabdomyosarcoma

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in